[Evaluation of the phagocytosis disorders in myeloproliferative diseases based on data from the nitroblue tetrazolium reduction test].
Guseva
S A
SA
D000293:Adolescent; D000328:Adult; D000368:Aged; D001782:Blood Donors; D004926:Escherichia coli; D005260:Female; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood*; D009504:Neutrophils / Q000378:metabolism; D009580:Nitroblue Tetrazolium / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D010587:Phagocytosis; D013778:Tetrazolium Salts
D008070:Lipopolysaccharides; D013778:Tetrazolium Salts; D009580:Nitroblue Tetrazolium
Otsenka narusheniĭ fagotsitoza pri mieloproliferativnykh zabolevaniiakh po dannym testa vosstanovleniia nitrosinego tetrazoliia.